NO301576B1 - Fremgangsmåte for fremstilling av et farmasöytisk preparat med immunundertrykkende aktivitet - Google Patents

Fremgangsmåte for fremstilling av et farmasöytisk preparat med immunundertrykkende aktivitet Download PDF

Info

Publication number: NO301576B1
Authority: NO; Norway
Prior art keywords: component; preparation; fatty acid; components; preparations
Prior art date: 1989-02-09

Application number

NO900577A

Other languages

English (en)

Norwegian (no)

Other versions

NO900577D0 (no

NO900577L (no

Inventor

Birgit Hauer

Ulrich Posanski

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1990-02-07

Publication date

1997-11-17

1989-02-09 Priority claimed from GB898902898A external-priority patent/GB8902898D0/en

1989-02-09 Priority claimed from GB898902901A external-priority patent/GB8902901D0/en

1989-02-13 Priority claimed from GB898903147A external-priority patent/GB8903147D0/en

1989-02-17 Priority claimed from GB898903663A external-priority patent/GB8903663D0/en

1990-02-07 Application filed by Sandoz Ag filed Critical Sandoz Ag

1990-02-07 Publication of NO900577D0 publication Critical patent/NO900577D0/no

1990-08-10 Publication of NO900577L publication Critical patent/NO900577L/no

1997-11-17 Publication of NO301576B1 publication Critical patent/NO301576B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 148
238000000034 method Methods 0.000 title claims description 30
230000001506 immunosuppresive effect Effects 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 86
229960001265 ciclosporin Drugs 0.000 claims description 85
108010036949 Cyclosporine Proteins 0.000 claims description 84
229930182912 cyclosporin Natural products 0.000 claims description 67
239000000194 fatty acid Substances 0.000 claims description 39
235000014113 dietary fatty acids Nutrition 0.000 claims description 37
229930195729 fatty acid Natural products 0.000 claims description 37
-1 poly(vinylpyrrolidone) Polymers 0.000 claims description 30
239000007787 solid Substances 0.000 claims description 27
239000006104 solid solution Substances 0.000 claims description 25
150000004665 fatty acids Chemical class 0.000 claims description 23
229930006000 Sucrose Natural products 0.000 claims description 21
239000005720 sucrose Substances 0.000 claims description 21
239000002552 dosage form Substances 0.000 claims description 19
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 18
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
239000000243 solution Substances 0.000 claims description 18
239000002775 capsule Substances 0.000 claims description 17
229930105110 Cyclosporin A Natural products 0.000 claims description 15
229920000642 polymer Polymers 0.000 claims description 14
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 14
208000023275 Autoimmune disease Diseases 0.000 claims description 13
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 13
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 13
239000000825 pharmaceutical preparation Substances 0.000 claims description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
229920005862 polyol Polymers 0.000 claims description 8
KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 claims description 6
229920001558 organosilicon polymer Polymers 0.000 claims description 6
229940032085 sucrose monolaurate Drugs 0.000 claims description 6
238000010438 heat treatment Methods 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 4
150000003077 polyols Chemical class 0.000 claims description 4
239000000155 melt Substances 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
229940057995 liquid paraffin Drugs 0.000 claims description 2
239000013543 active substance Substances 0.000 claims 3
239000012895 dilution Substances 0.000 claims 1
238000010790 dilution Methods 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
239000000047 product Substances 0.000 description 30
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
239000004094 surface-active agent Substances 0.000 description 20
108010036941 Cyclosporins Proteins 0.000 description 18
238000002560 therapeutic procedure Methods 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
239000007788 liquid Substances 0.000 description 13
238000002844 melting Methods 0.000 description 13
230000008018 melting Effects 0.000 description 13
239000000203 mixture Substances 0.000 description 13
229920001223 polyethylene glycol Polymers 0.000 description 13
239000000463 material Substances 0.000 description 11
238000007127 saponification reaction Methods 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
239000003381 stabilizer Substances 0.000 description 9
239000003921 oil Substances 0.000 description 8
235000019198 oils Nutrition 0.000 description 8
108010010803 Gelatin Proteins 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000008273 gelatin Substances 0.000 description 7
229920000159 gelatin Polymers 0.000 description 7
235000019322 gelatine Nutrition 0.000 description 7
235000011852 gelatine desserts Nutrition 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
238000012360 testing method Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
235000010980 cellulose Nutrition 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
230000001363 autoimmune Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
125000005456 glyceride group Chemical group 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000011630 iodine Substances 0.000 description 5
230000001926 lymphatic effect Effects 0.000 description 5
239000012188 paraffin wax Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
238000005809 transesterification reaction Methods 0.000 description 5
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
206010052779 Transplant rejections Diseases 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000002156 mixing Methods 0.000 description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
125000005375 organosiloxane group Chemical group 0.000 description 4
229920001515 polyalkylene glycol Polymers 0.000 description 4
229910052710 silicon Inorganic materials 0.000 description 4
239000010703 silicon Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
150000005690 diesters Chemical class 0.000 description 3
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000010419 fine particle Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000007892 solid unit dosage form Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
229920003148 Eudragit® E polymer Polymers 0.000 description 2
229920003136 Eudragit® L polymer Polymers 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
229920003091 Methocel™ Polymers 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
229920003072 Plasdone™ povidone Polymers 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
230000007815 allergy Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000002141 anti-parasite Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000004820 blood count Methods 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
KWABLUYIOFEZOY-UHFFFAOYSA-N dioctyl butanedioate Chemical compound CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC KWABLUYIOFEZOY-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
125000003827 glycol group Chemical group 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000003589 nefrotoxic effect Effects 0.000 description 2
231100000381 nephrotoxic Toxicity 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
229920000058 polyacrylate Polymers 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
238000003860 storage Methods 0.000 description 2
150000004043 trisaccharides Chemical group 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
229940114072 12-hydroxystearic acid Drugs 0.000 description 1
OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229910002014 Aerosil® 130 Inorganic materials 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
208000004883 Lipoid Nephrosis Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
ZFFCNTZCHDDATQ-UWFDMBNGSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexanoate Chemical compound CCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZFFCNTZCHDDATQ-UWFDMBNGSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical class CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
238000006136 alcoholysis reaction Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
102000004139 alpha-Amylases Human genes 0.000 description 1
108090000637 alpha-Amylases Proteins 0.000 description 1
229940024171 alpha-amylase Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229920006026 co-polymeric resin Polymers 0.000 description 1
201000003486 coccidioidomycosis Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
108010019251 cyclosporin H Proteins 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
108010040781 dihydrocyclosporin D Proteins 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960000878 docusate sodium Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000012332 laboratory investigation Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229940016590 sarkosyl Drugs 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000000779 smoke Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical group [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
229950004959 sorbitan oleate Drugs 0.000 description 1
229950003429 sorbitan palmitate Drugs 0.000 description 1
229950011392 sorbitan stearate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000003445 sucroses Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
229940045136 urea Drugs 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
239000010497 wheat germ oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Transplantation (AREA)
Hematology (AREA)
Neurology (AREA)
Biophysics (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO900577A 1989-02-09 1990-02-07 Fremgangsmåte for fremstilling av et farmasöytisk preparat med immunundertrykkende aktivitet NO301576B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB898902898A GB8902898D0 (en)	1989-02-09	1989-02-09	Improvements in or relating to organic compounds
GB898902901A GB8902901D0 (en)	1989-02-09	1989-02-09	Improvements in or relating to organic compounds
GB898903147A GB8903147D0 (en)	1989-02-13	1989-02-13	Improvements in or relating to organic compounds
GB898903663A GB8903663D0 (en)	1989-02-17	1989-02-17	Improvements in or relating to organic compounds

Publications (3)

Publication Number	Publication Date
NO900577D0 NO900577D0 (no)	1990-02-07
NO900577L NO900577L (no)	1990-08-10
NO301576B1 true NO301576B1 (no)	1997-11-17

Family

ID=27450262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO900577A NO301576B1 (no)	1989-02-09	1990-02-07	Fremgangsmåte for fremstilling av et farmasöytisk preparat med immunundertrykkende aktivitet

Country Status (25)

Country	Link
JP (3)	JP3484190B2 (it)
KR (1)	KR0170769B1 (it)
AT (1)	AT404552B (it)
AU (1)	AU630413B2 (it)
BE (1)	BE1003009A5 (it)
CA (1)	CA2009533C (it)
CH (1)	CH679277A5 (it)
CY (1)	CY1903A (it)
DE (1)	DE4003844B4 (it)
DK (1)	DK176209B1 (it)
ES (1)	ES2021942A6 (it)
FI (1)	FI97524C (it)
FR (1)	FR2642650B1 (it)
GB (1)	GB2230440B (it)
HK (1)	HK37296A (it)
HU (1)	HU213394B (it)
IT (1)	IT1240758B (it)
LU (1)	LU87675A1 (it)
MY (1)	MY107377A (it)
NL (1)	NL195028C (it)
NO (1)	NO301576B1 (it)
NZ (1)	NZ232401A (it)
PH (1)	PH30917A (it)
PT (1)	PT93079B (it)
SE (1)	SE511398C2 (it)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
HU208491B (en) *	1990-11-27	1993-11-29	Gyogyszerkutato Intezet	Process for producing oral pharmaceutical composition containing cyclosporin
MX9201782A (es) †	1991-04-19	1992-10-01	Sandoz Ag	Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
GB9113872D0 (en) *	1991-06-27	1991-08-14	Sandoz Ag	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
EP0642332B1 (en)	1992-05-13	1997-01-15	Sandoz Ltd.	Ophthalmic compositions containing a cyclosporin
US5759566A (en) *	1992-07-28	1998-06-02	Poli Industria Chimica Spa	Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
EP1142568A1 (en)	1992-09-25	2001-10-10	Novartis AG	Pharmaceutical compositions containing cyclosporins
SK283442B6 (sk) †	1993-04-20	2003-07-01	Novartis Ag	Farmaceutický prípravok na orálne podanie
DE4412201A1 (de) *	1993-04-20	1994-11-10	Rentschler Arzneimittel	Neue pharmazeutische Zubereitungen zur oralen Verabreichung enthaltend Cyclosporin
DE4340781C3 (de) *	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) *	1994-02-25	1998-08-17	김충환	사이클로스포린-함유 분말 조성물
RU2158601C2 (ru)	1994-11-03	2000-11-10	Новартис Аг	Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения
US5679566A (en) *	1995-01-20	1997-10-21	University Of Massachusetts Medical Center	Yeast NMD2 gene
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
DE19549852B4 (de)	1995-11-29	2009-06-04	Novartis Ag	Cyclosporin enthaltende Präparate
US5798333A (en) *	1996-09-17	1998-08-25	Sherman; Bernard C.	Water-soluble concentrates containing cyclosporins
BR9807528A (pt)	1997-01-30	2000-03-14	Novartis Ag	Composições farmacêuticas isentas de óleo contendo ciclosporina a
AU762247B2 (en) *	1997-01-30	2003-06-19	Novartis Ag	Oil-free pharmaceutical compositions containing cyclosporin A
SI0969856T1 (en) *	1997-03-12	2005-06-30	Abbott Laboratories	Hydrophilic binary systems for the administration of cyclosporine
NZ328751A (en) *	1997-09-16	1999-01-28	Bernard Charles Sherman	Solid medicament containing an anionic surfactant and cyclosporin
US6447806B1 (en)	1999-02-25	2002-09-10	Novartis Ag	Pharmaceutical compositions comprised of stabilized peptide particles
US6979672B2 (en)	2002-12-20	2005-12-27	Polichem, S.A.	Cyclosporin-based pharmaceutical compositions
JP4521554B2 (ja) *	2004-03-31	2010-08-11	マイラン製薬株式会社	シクロスポリン製剤
CN101360485B (zh) *	2005-10-26	2013-04-17	班纳制药公司	作为胶囊填充物的基于亲水性载体的双重控释基质系统
EP2004203A4 (en) *	2006-03-28	2010-03-31	Javelin Pharmaceuticals Inc	FORMULATIONS OF DICLOFENAC AND CYCLODEXTRIN BETA WITH LOW DOSAGE
US7495024B2 (en)	2006-08-07	2009-02-24	Via Pharmaceuticals, Inc.	Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102008059201A1 (de) *	2008-11-27	2010-06-02	GÖPFERICH, Achim, Prof. Dr.	In situ präzipitierende Arzneistofflösungen
KR102146704B1 (ko)	2018-04-13	2020-08-21	가천대학교 산학협력단	사이클로스포린 A (CsA) 경피 및 피내 약물전달용 마이크로구조체
WO2023063376A1 (ja) *	2021-10-13	2023-04-20	中外製薬株式会社	ペプチド化合物及び界面活性剤を含む組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI65914C (fi) *	1978-03-07	1984-08-10	Sandoz Ag	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
JPS61280435A (ja) *	1985-04-04	1986-12-11	Kanji Takada	サイクロスポリン類のリンパ指向性製剤
NL8600050A (nl) *	1986-01-13	1987-08-03	Sanico Nv	Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
GB8602372D0 (en) *	1986-01-31	1986-03-05	Sandoz Ltd	Organic compounds
CA1290249C (en) *	1986-04-09	1991-10-08	Cetus Corporation	COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
AU617295B2 (en) *	1986-11-13	1991-11-28	Sloan-Kettering Institute For Cancer Research	Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
ATE95193T1 (de) *	1987-06-17	1993-10-15	Sandoz Ag	Cyclosporine und deren benutzung als arzneimittel.
JP2536876B2 (ja) *	1987-07-31	1996-09-25	寛治高田	シクロスポリンの溶解性粉末状製剤
US5756450A (en) *	1987-09-15	1998-05-26	Novartis Corporation	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
DE3830494B4 (de) *	1987-09-15	2006-05-18	Novartis Ag	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
HU205010B (en) *	1987-09-15	1992-03-30	Sandoz Ag	Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
JP2792862B2 (ja) *	1988-07-30	1998-09-03	寛治高田	経口腸溶製剤
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
JPH1038029A (ja) *	1996-07-26	1998-02-13	Ebara Corp	制振機能付き円板状構造物
JPH10280435A (ja) *	1997-04-03	1998-10-20	Sekisui Chem Co Ltd	地下室の構築方法

1990
- 1990-02-05 BE BE9000133A patent/BE1003009A5/fr not_active IP Right Cessation
- 1990-02-05 CH CH359/90A patent/CH679277A5/de not_active IP Right Cessation
- 1990-02-05 FR FR9001389A patent/FR2642650B1/fr not_active Expired - Lifetime
- 1990-02-05 GB GB9002504A patent/GB2230440B/en not_active Expired - Lifetime
- 1990-02-07 LU LU87675A patent/LU87675A1/fr unknown
- 1990-02-07 FI FI900604A patent/FI97524C/fi active IP Right Grant
- 1990-02-07 NO NO900577A patent/NO301576B1/no not_active IP Right Cessation
- 1990-02-07 SE SE9000441A patent/SE511398C2/sv not_active Application Discontinuation
- 1990-02-07 NZ NZ232401A patent/NZ232401A/en unknown
- 1990-02-07 HU HU90701A patent/HU213394B/hu unknown
- 1990-02-07 MY MYPI90000191A patent/MY107377A/en unknown
- 1990-02-07 PT PT93079A patent/PT93079B/pt not_active IP Right Cessation
- 1990-02-07 PH PH40014A patent/PH30917A/en unknown
- 1990-02-07 CA CA002009533A patent/CA2009533C/en not_active Expired - Lifetime
- 1990-02-07 DK DK199000327A patent/DK176209B1/da not_active IP Right Cessation
- 1990-02-08 AT AT0027290A patent/AT404552B/de not_active IP Right Cessation
- 1990-02-08 KR KR1019900001492A patent/KR0170769B1/ko not_active IP Right Cessation
- 1990-02-08 IT IT47609A patent/IT1240758B/it active IP Right Grant
- 1990-02-08 NL NL9000299A patent/NL195028C/nl not_active IP Right Cessation
- 1990-02-08 AU AU49252/90A patent/AU630413B2/en not_active Expired
- 1990-02-08 DE DE4003844A patent/DE4003844B4/de not_active Expired - Lifetime
- 1990-02-08 JP JP03134890A patent/JP3484190B2/ja not_active Expired - Lifetime
- 1990-02-09 ES ES9000397A patent/ES2021942A6/es not_active Expired - Lifetime
1996
- 1996-03-07 HK HK37296A patent/HK37296A/xx not_active IP Right Cessation
- 1996-11-22 CY CY190396A patent/CY1903A/xx unknown
2001
- 2001-04-25 JP JP2001127538A patent/JP4073641B2/ja not_active Expired - Lifetime
2005
- 2005-09-13 JP JP2005265724A patent/JP2006001947A/ja active Pending

Also Published As

Publication number	Publication date
JP4073641B2 (ja)	2008-04-09
PH30917A (en)	1997-12-23
FR2642650A1 (fr)	1990-08-10
DK32790A (da)	1990-08-10
FI97524C (fi)	1997-01-10
CH679277A5 (it)	1992-01-31
GB2230440B (en)	1993-05-19
JPH02235817A (ja)	1990-09-18
FR2642650B1 (fr)	1994-12-09
FI900604A0 (fi)	1990-02-07
JP2006001947A (ja)	2006-01-05
IT9047609A1 (it)	1991-08-08
SE9000441L (sv)	1991-08-08
HU213394B (en)	1997-06-30
GB2230440A (en)	1990-10-24
AU4925290A (en)	1990-08-16
DK32790D0 (da)	1990-02-07
JP3484190B2 (ja)	2004-01-06
CY1903A (en)	1996-11-22
SE511398C2 (sv)	1999-09-20
AU630413B2 (en)	1992-10-29
NL195028C (nl)	2003-12-02
SE9000441D0 (sv)	1990-02-07
NO900577D0 (no)	1990-02-07
CA2009533C (en)	2002-11-12
IT9047609A0 (it)	1990-02-08
GB9002504D0 (en)	1990-04-04
DK176209B1 (da)	2007-02-05
NL9000299A (nl)	1990-09-03
NZ232401A (en)	1992-10-28
AT404552B (de)	1998-12-28
LU87675A1 (fr)	1991-10-08
HK37296A (en)	1996-03-15
KR900012625A (ko)	1990-09-01
BE1003009A5 (fr)	1991-10-22
FI97524B (fi)	1996-09-30
JP2001302538A (ja)	2001-10-31
ES2021942A6 (es)	1991-11-16
IT1240758B (it)	1993-12-17
HU900701D0 (en)	1990-04-28
NO900577L (no)	1990-08-10
NL195028B (nl)	2003-08-01
CA2009533A1 (en)	1990-08-09
MY107377A (en)	1995-11-30
DE4003844B4 (de)	2007-09-20
PT93079B (pt)	1996-04-30
ATA27290A (de)	1998-05-15
PT93079A (pt)	1990-08-31
DE4003844A1 (de)	1990-08-16
KR0170769B1 (ko)	1999-02-01

Publication	Publication Date	Title
NO301576B1 (no)	1997-11-17	Fremgangsmåte for fremstilling av et farmasöytisk preparat med immunundertrykkende aktivitet
US5756450A (en)	1998-05-26	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
KR100446170B1 (ko)	2004-11-20	사이클로스포린을함유하는약학조성물
KR0150830B1 (ko)	1998-10-15	사이클로스포린 연질캅셀제 조성물
JPH0611703B2 (ja)	1994-02-16	新規シクロスポリン製剤
US6187747B1 (en)	2001-02-13	Pharmaceutical composition comprising cyclosporin
NO179434B (no)	1996-07-01	Fremgangsmåte for fremstilling av et farmasöytisk preparat, og anvendelse av en vannopplöselig monoester som et solubiliserende middel
EP0982035B1 (en)	2004-03-31	Cyclosporin composition comprising an hydrophilic carrier
EP1151755B1 (en)	2005-03-16	Pharmaceutical compositions comprising cyclosporin as active ingredient
AU716855B2 (en)	2000-03-09	Novel compositions containing cyclosporin
US6346511B1 (en)	2002-02-12	Pharmaceutical composition comprising cyclosporin
KR100525234B1 (ko)	2005-10-28	사이클로스포린 함유 연질캅셀제 및 그 제조방법
IE900434L (en)	1990-08-09	Novel cyclosporin galenic forms
RU2207870C2 (ru)	2003-07-10	Фармацевтическая композиция, включающая циклоспорин в качестве активного ингредиента
KR100256007B1 (ko)	2000-05-01	사이클로스포린을 함유하는 약학 조성물
KR100267149B1 (ko)	2000-09-15	사이클로스포린을 함유하는 약학 조성물
CZ20012999A3 (cs)	2002-04-17	Farmaceutický prostředek obsahující cyklosporin a způsob jeho přípravy

Legal Events

Date	Code	Title	Description
2010-02-22	MK1K	Patent expired